Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 642,400 shares, a decrease of 55.7% from the January 15th total of 1,450,700 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 6,424.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of OTCMKTS:BIOVF remained flat at $30.48 during trading on Friday. The company’s 50-day moving average is $28.68 and its 200 day moving average is $28.81. The firm has a market cap of $10.85 billion, a PE ratio of 51.66 and a beta of 0.53. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73. Swedish Orphan Biovitrum AB has a fifty-two week low of $22.87 and a fifty-two week high of $32.25.

Wall Street Analyst Weigh In

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.